A phase III trial—results of which were published by Rodriguez-Otero in The New England Journal of Medicine—compared the efficacy of idecabtagene vicleucel (ide-cel), a chimeric antigen receptor (CAR) T-cell therapy, to five other standard regimens in patients with relapsed and refractory multiple myeloma.
